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Abstract
Autism spectrum disorders (ASD) are highly disabling developmental disorders with a population prevalence of 1–3%.
Despite a strong genetic etiology, there are no current therapeutic options that target the core symptoms of ASD. Emerging
evidence suggests that dysfunction of glutamatergic signaling, in particular through metabotropic glutamate receptor 5
(mGluR5) receptors, may contribute to phenotypic deficits and may be appropriate targets for pharmacologic intervention.
This study assessed the therapeutic potential of 2-methyl-6-phenylethyl-pyrididine (MPEP), an mGluR5-receptor antagonist,
on repetitive and anxiety-like behaviors in the valproic acid (VPA) mouse model of autism. Mice were exposed prenatally on
day E13 to VPA and assessed for repetitive self-grooming and marble burying behaviors as adults. Anxiety-like behavior and
locomotor activity were measured in an open-field. VPA-exposed mice displayed increased repetitive and anxiety-like
behaviors, consistent with previously published results. Across both marble burying and self-grooming assays, MPEP
significantly reduced repetitive behaviors in VPA-treated mice, but had no effect on locomotor activity. These results are
consistent with emerging preclinical literature that mGluR5-antagonists may have therapeutic efficacy for core symptoms of
autism.
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Introduction
Autism spectrum disorders (ASD) are neurodevelopmental
disorders characterized by repetitive and restricted patterns of
behavior, reduced social interactions, and impairments in language
function. Recent estimates suggest that autism has a population
prevalence of 1–3%, with symptom onset beginning within the first
three years of life [1,2,3]. Although not considered diagnostic
symptoms, autism is characterized by a number of neurological and
psychiatric comorbidities, such as anxiety. Of the core domains,
repetitive behaviors are of particular interest because they are the
strongest predictor that an early diagnosis of ASD will persist
throughout the lifetime [4]. These behaviors, with a similarity to
symptoms of obsessive-compulsive disorder (OCD), include stereo-
typic movements, repetitive play, inflexible routines, and a ritualistic
insistence on sameness [5]. When such behaviors are interrupted, a
child may protest or exhibit anxiety or aggression [5]. The severity
of many of these disorders, combined with the high prevalence
rates, highlights the need for the development of biological
interventions. However, second generation antipsychotics, such as
risperidone, are the only FDA-approved class of medications for the
treatment of ASD. There is some evidence that risperidone may
improve repetitive,restricted interestsand behaviorsinsubjectswith
autism [6,7], one of the core symptomatic domains, although results
are mixed [8,9]. Treatment with risperidone is generally limited to
patients who display certain associated maladaptive behaviors, such
as irritability, aggression, and self-injury [10,11], as the drug has a
significant side-effect profile, including weight gain and metabolic
syndrome, which complicate its therapeutic potential [12]. As such,
there is a strong need to develop novel therapeutic approaches that
target core deficits (and pathophysiology) of autism, while limiting
adverse effects.
Investigation of novel therapeutics requires a robust preclinical
paradigm with a validated animal model that displays phenotypes
analogous to the core symptoms of autism. We recently
demonstrated that a single prenatal (embryonic day 13) exposure
to the anticonvulsant valproic acid (VPA), which is associated with
a 7–10 fold increased relative risk for ASD in humans,
recapitulates selective behavioral and electrophysiological deficits
in mice analogous to those seen in the clinical population
[13,14,15]. In particular, VPA-exposed mice demonstrated
increased repetitive self-grooming behaviors, decreased social
preference, and reduced emission of ultrasonic vocalizations
thought to reflect communicative dysfunction [15]. Similar
findings have been reported in rats exposed to VPA in utero,
bolstering the validity of this model [16].
Current theories of ASD pathogenesis attribute symptoms to the
disrupted balance of excitatory/inhibitory signaling during critical
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prenatal VPA exposure causes lasting changes in neural circuitry
leading to heighted excitation and reduced inhibition. Such
disruptions may be restored by targeted pharmacotherapeutic
agents that improve excitatory-inhibitory balance. Glutamate is
the main excitatory neurotransmitter in the brain and utilizes two
different receptor types, ionotropic and metabotropic G-protein
coupled receptors. Emerging evidence implicates disrupted
glutamatergic signaling in autism and related disorders, in
particular signaling that involves the metabotropic glutamate
receptor 5 (mGluR5) receptor [19,20]. As such, recent preclinical
work has investigated the therapeutic potential of 2-methyl-6-
phenylethyl-pyrididine Specifically, MPEP reduced stereotypies in
the BTBR mouse model of autism [21] and reversed ASD-like
endophenotypes in the VPA mouse model [15].
This study sought to extend these previous findings by
investigating the potential therapeutic effects of MPEP on
repetitive behaviors in the VPA mouse model of ASD. We chose
to start by measuring repetitive self-grooming and marble burying
behaviors, two motor stereotypies that have been previously
investigated in ASD mouse models, as the more complex
insistence on sameness has yet to be fully investigated with
pharmacology in mice. Finally, we employed open field and
locomotor activity paradigms to assess potentially confounding
sedative effects of MPEP and the possibility that the efficacy of
MPEP may be due to its anxiolytic properties.
Materials and Methods
Animals
C57BL/6Hsd (B6) mice were obtained at 7–8 weeks of age from
Harlan (Indianapolis, Indiana) and were mated, with pregnancy
confirmed by the presence of a vaginal plug on embryonic day 0
(E0). On E13, pregnant females received a single subcutaneous
injection of 600 mg/kg VPA (Tocris BioScience, Ellisville,
Missouri) dissolved in saline (SAL). Control females received an
equal volume of SAL only. There were 56 pups delivered from 10
VPA-treated dams, and 34 pups from 6 SAL-treated females. Of
those, 24 pups from VPA-treated dams and 24 pups from SAL-
treated dams were used in this study. Day of birth was recorded as
P0. Animals were maintained in a standard 12-hour light/dark
cycle with free access to food and water. The same 24 mice were
used in each assay per group. Half of each group received an
injection of MPEP prior to each assay, while the rest received an
injection of vehicle. Behavioral testing was performed in the
following order: self-grooming, locomotor activity/open field, and
marble burying. There were on average 16 days between self-
grooming and locomotor activity testing sessions and 7 days
between LMA and marble burying testing. All protocols were
approved by the University of Pennsylvania Institutional Animal
Care and Use Committees and were conducted in accordance
with National Institutes of Health guidelines.
Self-Grooming Assay
Mice were scored for spontaneous grooming time as a measure
of repetitive behavior from P42 to P50, according to our published
methods [15]. Each mouse was placed in a clean empty plastic
cage in white light (400 lux) for a 10-minute acclimation period.
Bedding was not used in order to prevent digging, a potentially
competitive repetitive behavior. Following acclimation, mice were
scored with a stopwatch for cumulative time spent self-grooming
during a 10-minute testing period. Between each testing period,
the cage was cleaned with 70% ethanol, left to dry for 5 minutes,
and wiped down with a clean paper towel.
Open Field and Locomotor Testing
From P56 to P64, assessment of anxiety-like behavior and
locomotor activity was performed in a (50635640 cm) open field
as published, on average 16 days after testing in the self-grooming
assay [15]. Briefly, mice were placed individually in the periphery
of the open field boxes covered with 2 cm of bedding under white
light (400 lux) for 30 minutes. Video was digitally recorded and
movements were traced with TopScan software (CleverSys,
Reston, VA). A peripheral (11 cm width) and a central zone
(30 cm611 cm) were defined and the movements of each mouse
were traced. Anxiety-like behavior was assessed for each mouse by
the number of entries into the center zone, as well as the time
spent in this region during the first ten minutes of the testing
session. Locomotor activity was recorded as total distance traveled
(mm per minute) for each mouse and significance was assessed
with a group x drug x minute repeated-measures ANOVA.
Marble Burying Assay
Mice were assessed in the marble-burying assay from P65 to P71,
on average 7 days after open field testing. Mice were allowed to
acclimate individually in a (50635640 cm) cage filled with 4 cm of
fresh bedding for 15 minutes in white light (400 lux). To minimize
neophobia and novelty-induced anxiety, mice had been previously
exposed to the testing arena during locomotor and open field testing.
Following acclimation, mice were removed from the cage, and 20
black marbles were placed equidistant in a 465 arrangement. Mice
were then returned to the same cage for 30 minutes. Following the
30-minute testing period, the number of marbles that weremore than
two-thirds covered with bedding were counted by a single blinded
experimenter. After each testing period, the cage was cleaned with
70% ethanol,left to dry for 5 minutes,wiped down with a clean paper
towel, and fresh bedding was then added.
Pharmacology
2-methyl-6-phenylethynyl-pyridine (MPEP) was obtained from
Sigma and dissolved in 0.9% saline at 20 mg/kg prior to testing
session. Dosages were based on previous publications demonstrat-
ing efficacy in mice [21]. Intraperitoneal injections of saline vehicle
or drug were given 10 minutes before onset of behavioral assays.
Previous work has demonstrated that the maximal occupancy of
MPEP at mGluR5 receptors in mouse forebrain occurs 10 minutes
after i.p. injection [22].
Statistical Methods
For each behavior, statistical significance was assessed with a group
(SAL, VPA) x drug (VEHICLE, MPEP) ANOVA using GraphPad
Prism software (v5, La Jolla, CA). Where appropriate, Bonferroni
post-tests were calculated to determine significance between
individual groups using the GraphPad Prism post-test calculator
(http://www.graphpad.com/quickcalcs/posttest1.cfm). For locomo-
tor activity, statistical significance was assessed with a group (SAL,
VPA) x drug (VEHICLE, MPEP) x minute (1–30) repeated-measures
ANOVA using Statistica software (v6, Tulsa, OK).
Results
Repetitive Self-Grooming Behavior
The self-grooming assay was used to test the effects of MPEP on
repetitive behavior in mice exposed prenatally to valproic acid
(VPA) and saline (SAL). Self-grooming activity has been widely
employed as an index of repetitive behavior relevant to the core
symptom domain in several other preclinical studies of autism
[20,21,23,24]. A main effect of group (F(1,47)=9.361, P,0.004)
indicated that VPA-exposed mice groomed themselves significant-
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session, consistent with previous results (Fig 1a) [15]. In addition,
treatment with MPEP significantly reduced self-grooming behav-
ior across both groups (F(1,47)=7.10, P=0.011). There was no
significant group by drug interaction. Drug effects were driven by
the VPA group, which was significantly different between drug
conditions (P,0.04, Bonferroni post-test), whereas the SAL group
did not differ between vehicle and MPEP treatments (P.0.05,
Bonferroni post-test). In addition, the grooming times of the
MPEP treated VPA-exposed mice were comparable to those of the
vehicle treated SAL-exposed mice (P.0.05, Bonferroni post-test).
These results demonstrate that MPEP normalizes the increased
repetitive behaviors following in utero VPA exposure.
Marble Burying Assay
In addition, we assessed the effect of MPEP on marble burying
activity in VPA- and SAL-exposed mice. This assay has been
employed as a measure of anxiety-like and repetitive OCD-like
behaviors in mice, although it has been debated which domain it
more closely evaluates [25]. VPA-exposed mice buried signifi-
cantly more marbles than did SAL-exposed mice, consistent with
an increase in stereotyped, perseverative behaviors (F(1,46)=4.25,
P,0.05; Fig 1b). When treated with MPEP, the number of
marbles buried was significantly reduced across both groups
(F(1,46)=8.20, P=0.006). There was no significant group by drug
interaction. Again, although there was a main effect of drug across
both groups, post-tests revealed that this effect was driven by the
VPA group. Marble burying was significantly reduced in VPA-
exposed mice treated with MPEP compared to vehicle (P,0.01,
Bonferroni post-test). However, in the SAL-exposed group, there
was no difference between vehicle and MPEP conditions (P.0.05,
Bonferroni post-test). Finally, the number of marbles buried by
MPEP treated VPA-exposed mice was comparable to those buried
by vehicle treated SAL-exposed mice (P.0.05, Bonferroni post-
test). These results further demonstrate that MPEP is effective at
reducing the increase in stereotyped, repetitive marble burying
caused by prenatal VPA exposure.
Open Field Testing
To determine if the effect of MPEP was mediated simply by
reducing anxiety-like behavior in the VPA group, we next assessed
this behavioral domain with an open-field paradigm. Consistent
with previous reports of increased anxiety-like behavior in this
model [15,26], VPA-exposed mice exhibited significantly fewer
center entries than SAL-exposed mice (F(1,43)=5.65, P=0.02;
Fig 2a), although center time did not reach statistical significance
between groups (F(1,43)=2.85, P=0.09; Fig 2b). There was no
effect of MPEP on the number of center entries (F(1,43)=0.61,
P=0.44) or percentage of time spent in center (F(1,43)=1.46,
P=0.23). These results indicate that the positive effect of MPEP
on stereotyped, perseverative behaviors in the VPA model is not
likely mediated by reducing concomitant anxiety-like behavior.
Locomotor Activity
Finally, a sedating drug effect could potentially confound
observed results in marble burying and self-grooming assays. To
address this, the effect of MPEP was assessed on locomotor activity
(LMA) in VPA- and SAL-exposed mice over a 30-minute testing
session. Significance was assessed with a group x drug x minute
repeated measures ANOVA. Consistent with our previous
findings, VPA-treated mice showed no difference in baseline
LMA compared with SAL controls (F(1,43)=0.24, P=0.63) [15].
Likewise, there was no significant effect of MPEP on LMA
(F(1,43)=3.17, P=0.09; Fig 3), nor was there a significant group
by drug interaction (F(1,43)=0.04, P=0.84). Although not
significant, there was a qualitative trend towards increased
locomotor activity with MPEP, mediated mostly by the first 5-
minutes of testing, after which drug conditions were indistinguish-
able among groups. This suggests that overly sedating effects of
MPEP did not confound the repetitive and anxiety-like behavioral
results reported above.
Discussion
The present study investigated the effects of the mGluR5
antagonist MPEP on measures of anxiety and stereotyped,
repetitive behaviors in a mouse model relevant to autism. We
demonstrate that MPEP displays efficacy in reducing repetitive
self-grooming and marble burying behaviors in mice exposed in
utero to valproic acid. There was no effect of MPEP on anxiety-like
behavior in an open field paradigm, nor were our results
confounded by overly sedating pharmacological effects.
Figure 1. The mGluR5-receptor antagonist MPEP attenuates elevated repetitive behaviors in mice exposed to valproic acid (VPA) in
utero. (A) Repetitive self-grooming was measured over 10 minutes in mice exposed to prenatal saline (SAL) or VPA. (B) Repetitive marble burying
behavior was measured for both groups after a 30 minute testing session. Across both assays, VPA-exposed mice demonstrated elevated
stereotyped, repetitive behaviors that were significantly reduced by MPEP. Figures show mean 6 S.E.M., (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0026077.g001
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These findings complement previous work demonstrating
positive effects of mGluR5 antagonists on phenotypic deficits
relevant to the core symptoms of autism in preclinical studies. Of
note, Silverman and colleagues demonstrated a similar reduction
in repetitive behaviors following MPEP administration in BTBR
mice, an inbred genetic model relevant to ASD [21]. In the VPA
mouse model, we previously showed that MPEP reverses autism-
like endophenotypes, including deficits in prepulse inhibition (PPI)
and reduced auditory-evoked gamma frequency synchrony [15].
Likewise, a number of studies have shown that mGluR5
antagonists are effective in reversing neural deficits in preclinical
models of Fragile X Syndrome (FXS), which shares a high degree
of overlap with autism. For example, MPEP has been demon-
strated to reverse PPI and dendritic spine abnormalities in Fmrp1
knockout mice, as well as restore social courtship behavior defects
in a Drosophila model of the disease [27,28]. Demonstrating positive
therapeutic effects of this drug across several distinct preclinical
models bolsters the robustness of these findings and the
generalizability of the therapeutic potential of mGluR5 antagonists
for the treatment of autism. MPEP has also displayed analgesic
and anxiolytic actions in other models of disease, properties that
can also benefit patients with autism who often exhibit increased
sensitivity to sensory stimuli, as well as anxious and self-injurious
behaviors [21,29,30,31].
The effectiveness of MPEP in reducing stereotypic behaviors fits
with emerging evidence that glutamatergic dysfunction may
contribute to core deficits in autism [19,20,32]. Current theories
of disease pathogenesis implicate a disrupted balance of excitation
and inhibition, a balance that may be restored by blocking
mGluR5 receptors [15,17]. Indeed, previous work has shown that
mice exposed in utero to VPA have elevated glutamatergic signaling
and hyperexcitable local circuitry [33,34], which likely contributes
to the abnormal phenotypes seen in this model. Increased
excitatory signaling could be attributed to reduced inhibition, as
previous work has also demonstrated a loss of parvalbumin-
expressing interneurons following in utero VPA exposure [18].
Collectively, these findings suggest that attenuating elevated
glutamatergic signaling, with drugs like MPEP, could ameliorate
behavioral abnormalities in the VPA model, as we have shown in
Figure 2. The effect of MPEP was assessed on anxiety-like behavior in VPA- and SAL-exposed mice using an open-field paradigm.
Consistent with elevated anxiety, VPA-exposed mice demonstrated significantly fewer (A) center entries and qualitatively reduced (B) center time.
Across groups, there was no effect of MPEP on either of these measures. Figures show mean 6 S.E.M., (#p,0.1, *p,0.05).
doi:10.1371/journal.pone.0026077.g002
Figure 3. The effect of MPEP on spontaneous locomotor
activity (LMA) was assessed across groups as sedative effects
could potentially confound findings in other behavioral
assays. As previously reported, there was no significant difference in
locomotor activity between groups. Likewise, MPEP did not significantly
alter locomotor activity in (A) SAL- or (B) VPA-exposed mice over the 30
minute testing session. MPEP caused a qualitative increase in LMA
across groups, but only for the first 5 minutes following drug injection,
further supporting a lack of sedative effects.
doi:10.1371/journal.pone.0026077.g003
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mediated currents, as mGluR5 receptors are known to reciprocally
modulate NMDAR signaling [35]. Finally, there is growing
evidence that glutamate-modulating agents may be efficacious in
treatment-resistant OCD, further demonstrating the role of
glutamatergic systems in stereotypic behaviors [36].
MPEP and Anxiety
It has been difficult to separate repetitive OCD-like and anxiety-
like behaviors, particularly in preclinical studies. For example,
OCD is considered an anxiety disorder, and there is frequently
significant clinical overlap between OCD and generalized anxiety
disorder [37]. Several mouse behavioral paradigms have been
proposed to assess the repetitive, restricted behaviors and
insistence on sameness, which comprise the third core symptom-
atic domain of autism [24,38,39,40,41,42]. T-maze and water-
maze reversal learning paradigms have been proposed to reflect
cognitive inflexibility, whereas marble burying and self-grooming
have been widely employed as measures of motor stereotypies.
However, both marble burying and self-grooming assays have also
been shown to be sensitive to anxiety [43,44], although there is
some controversy as to which behavior each task is most sensitive
[25,45].
Our data demonstrate that acute administration of MPEP is
sufficient to reduce elevated self-grooming and marble burying
behaviors in VPA-exposed mice but has no effect on open-field
activity, a traditional test for anxiety-like behaviors. However, our
results do not definitively demonstrate that these effects are
independent of the anxiolytic effects of MPEP. Several additional
tests of anxiety-like behaviors, such as light-dark exploration and
open arm entries on an elevated plus-maze, would be required to
conclusively rule out the possibility that the effects of MPEP are
mediated by anxiolysis. Nevertheless, reducing stereotyped,
repetitive behaviors as well as anxiety-like behaviors would both
be beneficial for autism, given that individuals with ASD
frequently have comorbid anxiety disorders [3].
Limitations and Future Directions
In conclusion, our results support the therapeutic potential of
MPEP for the treatment of repetitive, stereotyped behaviors
relevant to patients with autism. This study provides mechanistic
insight into the pathophysiology of OCD-like repetitive behaviors
relevant to autism. However, it is unclear whether MPEP, itself,
would be well tolerated in the clinical population and would thus
be a good drug candidate for clinical trials.
One limitation of our study is the generalizability of the VPA
mouse model to the ASD population. Although many of the
behavioral and neuropathological deficits following prenatal VPA
exposure mimic those seen in ASD patients, the majority of such
patients were not exposed to this drug in utero. However, the
efficacy of MPEP on repetitive behaviors replicated across multiple
preclinical ASD models of autism strengthens the predictive
validity of these findings.
Whereas our study did not find a significant effect of MPEP on
anxiety-like behavior across VPA- and SAL-treated mice, other
studies have reported anxiolytic effects of mGluR5 antagonists in
rodent models of anxiety using various behavioral paradigms
[46,47]. This discrepancy could reflect the use of lower doses,
acute (versus chronic) administration, different behavioral para-
digms, or the lack of a fear/stress-inducing behavioral test such as
one involving foot-shocks [47,48,49]. However, the observation
that MPEP was effective in reducing repetitive behaviors acutely in
the VPA model suggests that its efficacy towards these behaviors
may be more selective and/or more immediate than that for
anxiety.
Future studies will investigate the therapeutic potential of MPEP
on additional behaviors relevant to the core symptoms of autism
(e.g., social deficits). We chose to begin with stereotyped behaviors
given that previous work failed to find an effect of MPEP on
sociability in the BTBR model [21]. Likewise, future studies will
also attempt to further reconcile the distinct pharmacologic profile
of MPEP on anxiety versus OCD-like behaviors by employing a
chronic dosing strategy, as well as by utilizing additional measures
of anxiety and repetitive behavior in rodents.
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